Evidence map›Paper›PMID 34794791›Full record

ArticleHematology, transfusion and cell therapy2021

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia.

Adriana Seber, Claudio Galvão de CastroJunior, Lucila N Kerbauy, Alexandre V Hirayama, Carmem Bonfim, Juliana Folloni Fernandes, Mair Souza, Rony Schafell, Samir Nabhan, Sandra Regina Loggetto and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematology, transfusion and cell therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 3 countries.

Adriana SeberHospital Samaritano Higienópolis, São Paulo, SP, Brazil; Hospital Infantil Sabará, São Paulo, SP, Brazil.
Claudio Galvão de CastroJuniorHemomed Instituto de Oncologia e Hematologia, São Paulo, SP, Brazil; Hospital São Camilo, São Paulo, SP, Brazil.
Lucila N KerbauyHospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Alexandre V HirayamaFred Hutchinson Cancer Research Center, Seattle, WA, EUA.
Carmem BonfimHospital Pequeno Príncipe, Curitiba, PR, Brazil; Hospital de Clínicas, Universidade Federal do Paraná (HC UFPR), Curitiba, PR, Brazil.
Juliana Folloni FernandesHospital Israelita Albert Einstein, São Paulo, SP, Brazil; Instituto do Tratamento do Câncer Infantil, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC FMUSP), São Paulo, SP, Brazil.
Mair SouzaHospital Amaral Carvalho, Jaú, SP, Brazil.
Rony SchafellHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro (HUCFF UFRJ), Rio de Janeiro, RJ, Brazil.
Samir NabhanHospital de Clínicas - Universidade Federal do Paraná, (HC UFPR), Curitiba, PR, Brazil.
Sandra Regina LoggettoHospital Infantil Sabará, São Paulo, SP, Brazil; Grupo Gestor de Serviços de Hematologia (GSH), São Paulo, SP, Brazil.
Belinda Pinto SimõesKolb Consulting UG, Munich, Germany.
Vanderson RochaHospital das Clínicas, Universidade de São Paulo, (HC USP), São Paulo, SP, Brazil; Hospital Vila Nova Star, São Paulo, SP, Brazil.
Marcos de LimaOhio State University, Columbus, OH, USA.
Renato L Guerino-CunhaFaculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil. Electronic address: rlgc@usp.br.
Henrique BittencourtCentre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Qc, Canada; Université de Montreal, Montreal, Qc, Canada.
Hospital Israelita Albert Einstein · BRCentre Hospitalier Universitaire Sainte-Justine · CAFred Hutch Cancer Center · USGrupo Hospitalar Conceição · BRHospital Amaral Carvalho · BRHospital de Clínicas Universidade Federal do Paraná · BRHospital Erasto Gaertner · BRHospital Samaritano de São Paulo · BRHospital Universitário da Universidade de São Paulo · BRSão Camilo Hospital · BRThe Ohio State University · USUniversidade de Ribeirão Preto · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.

Indexed as

Acute lymphoblastic leukemiaAcute lymphoid leukemiaAdoptive cellular therapyAdvanced cellular therapyCar-T cellsCellular therapyImmunotherapy

Identifiers

PMID34794791
PMCPMC8606700
OpenAlexW3212994588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.